Publication:
Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.

Simple item page
dc.contributor.authorBukkems, Vera
dc.contributor.authorNecsoi, Coca
dc.contributor.authorTenorio, Carmen Hidalgo
dc.contributor.authorGarcia, Coral
dc.contributor.authorRockstroh, Jürgen
dc.contributor.authorSchwarze-Zander, Caroline
dc.contributor.authorLambert, John S
dc.contributor.authorBurger, David
dc.contributor.authorKonopnicki, Deborah
dc.contributor.authorColbers, Angela
dc.date.accessioned2023-02-08T14:47:04Z
dc.date.available2023-02-08T14:47:04Z
dc.date.issued2020
dc.description.abstractThis phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.
dc.identifier.doi10.1093/cid/ciaa488
dc.identifier.essn1537-6591
dc.identifier.pmcPMC7744974
dc.identifier.pmid32330231
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744974/pdf
dc.identifier.unpaywallURLhttps://academic.oup.com/cid/article-pdf/71/10/e714/34933369/ciaa488.pdf
dc.identifier.urihttp://hdl.handle.net/10668/15427
dc.issue.number10
dc.journal.titleClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.journal.titleabbreviationClin Infect Dis
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.numbere714-e717
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHIV
dc.subjectcobicistat
dc.subjectelvitegravir
dc.subjectpharmacokinetics
dc.subjectpregnancy
dc.subject.meshAnti-HIV Agents
dc.subject.meshAnti-Retroviral Agents
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHumans
dc.subject.meshPregnancy
dc.subject.meshPregnancy Complications, Infectious
dc.subject.meshPregnancy Trimester, Third
dc.subject.meshPregnant Women
dc.subject.meshQuinolones
dc.titleClinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number71
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC7744974.pdf
Size:
121.94 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen de las Nieves

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía